Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

a-s medication solutions - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 25 mg - sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications ). safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. sumatriptan tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. in addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptane tablets. ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort, vasospastic forms of angina such as the prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. cerebrovascular syndromes include, but are not limited to, stro

Canada - Tiếng Anh - Health Canada

natco pharma (canada) inc - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 5mg - rizatriptan (rizatriptan benzoate) 5mg - selective serotonin agonists

Canada - Tiếng Anh - Health Canada

natco pharma (canada) inc - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 10mg - rizatriptan (rizatriptan benzoate) 10mg - selective serotonin agonists

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

a-s medication solutions - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan injection, usp is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. limitations of use: - use only if a clear diagnosis of migraine or cluster headache has been established. if a patient has no response to the first migraine or cluster headache attack treated with sumatriptan injection, usp, reconsider the diagnosis before sumatriptan injection, usp is administered to treat any subsequent attacks. - sumatriptan injection, usp is not indicated for the prevention of migraine or cluster headache attacks. sumatriptan injection is contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1)] . - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precau

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

mylan institutional llc - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. limitations of use: sumatriptan injection is contraindicated in patients with: risk summary data from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have not detected an increased frequency of birth defects or a consistent pattern of birth defects among women exposed to sumatriptan compared with the general population (see data). in developmental toxicity studies in rats and rabbits, oral administration of sumatriptan to pregnant animals was associated with embryolethality, fetal abnormalities, and pup mortality. when administered by the intravenous route to pregnant rabbits, sumatriptan was embryolethal (see data). in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the reported rate

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

sagent pharmaceuticals - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan injection, usp is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. limitations of use: - use only if a clear diagnosis of migraine or cluster headache has been established. if a patient has no response to the first migraine or cluster headache attack treated with sumatriptan injection, usp, reconsider the diagnosis before sumatriptan injection, usp is administered to treat any subsequent attacks. - sumatriptan injection, usp is not indicated for the prevention of migraine or cluster headache attacks. sumatriptan injection is contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1)] . - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precau

Canada - Tiếng Anh - Health Canada

nora pharma inc - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 5mg - rizatriptan (rizatriptan benzoate) 5mg - selective serotonin agonists

Canada - Tiếng Anh - Health Canada

nora pharma inc - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 10mg - rizatriptan (rizatriptan benzoate) 10mg - selective serotonin agonists

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

organon pharma (ireland) limited - rizatriptan benzoate - oral lyophilisate - 10 milligram(s) - selective serotonin (5ht1) agonists; rizatriptan

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

organon pharma (ireland) limited - rizatriptan - oral lyophilisate - 5 milligram(s) - selective serotonin (5ht1) agonists; rizatriptan